Neoadjuvant chemotherapy for epithelial ovarian cancer in Japan: a JSGO-JSOG joint study

Hiroko Machida,1,* Koji Matsuo,2,* Takayuki Enomoto,4 Mikio Mikami1

1Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan
2Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA
3Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
4Department of Obstetrics and Gynecology, Niigata University School of Medicine, Niigata, Japan

To the Editor,

The incidence of ovarian cancer is steadily increasing in Japan, with more than half of the women with ovarian cancer having advanced disease at presentation [1,2]. The standard treatment for epithelial ovarian cancer comprises primary debulking surgery (PDS), followed by platinum-based chemotherapy [3]. However, PDS is associated with a relatively high risk of morbidity and mortality because of its invasiveness. Previous studies demonstrated non-inferiority of overall survival in women with advanced ovarian cancer who received neoadjuvant chemotherapy followed by interval debulking surgery (NACT/IDS) compared with those who underwent PDS [4-6]. More recent approaches for the initial treatment of epithelial ovarian cancer may have changed. Therefore, we examined temporal trends in the utilization of NACT and changes in survival for epithelial ovarian cancer in Japan.

We conducted a retrospective observational study using data from the Japan Society of Obstetrics and Gynecology (JSOG) gynecological tumor registry database from 2002 to 2015 (n=48,426). This database is an organ-based cancer registry of gynecological malignancies that is supported and managed by the gynecologic tumor committee of JSOG; the database records cancer subtypes, characteristics, treatments, and survival data [7]. The present study was conducted after obtaining approval from our Institutional Review Board.

Information extracted from the database included patient demographics (age, area of registry, and calendar year at diagnosis), tumor histology (serous, mucinous, endometrioid, and clear cell), treatment type (staging surgery, including lymphadenectomy and NACT), and survival outcome (cause-specific survival (CSS)). Patients were classified by age according to the definition of the Ministry of Health, Labor and Welfare in Japan: non-elderly (<65 years), young-elderly (65–74 years), and elderly (≥75 years) [8,9].

The primary objective of this study was to examine time-specific trends of the proportion of women treated using NACT/IDS among patients with primary epithelial ovarian cancer in Japan. The secondary objective was to investigate the temporal trends of the 5-year CSS rate from 2002 to 2011.

Statistical analyses were performed as follows. Continuous variables were assessed using the Mann-Whitney U test or Student's t-test. Ordinal and categorical variables were analyzed...
using $\chi^2$-test. The Joinpoint Regression Program (version 4.7.0.0), provided by the National Cancer Institute (Bethesda, MD, USA), was utilized to evaluate temporal trends, which were analyzed using linear segmented regression [10]. Log transformation was then performed to determine the annual percent change of the slope with 95% confidence intervals (CIs). All hypotheses were 2-tailed, and values of $p<0.05$ were considered to indicate statistical significance. Statistical analysis was performed using Statistical Package for Social Sciences (version 25.0; IBM SPSS, Armonk, NY, USA).

Among 48,426 women, 5,153 (10.6%, 95% CI=10.3–10.9) received NACT (Supplementary Fig. 1). Women who received NACT were more likely to be old, have a recent diagnosis, and be residents of East Japan, but were less likely to be residents of West Japan ($p<0.05$ for all; Table 1). During the study period, there was a significant increase in the utilization of NACT among the entire cohort: 7.2% to 14.9% (2.1-fold increase, $p<0.001$; Fig. 1).

Stratification by patient age (Fig. 2) revealed a significant increase in NACT use among the 3 age groups, with the elderly group exhibiting the largest interval increase (non-elderly, 6.4% to 12.2% [90.6% relative increase, $p<0.001$]; young-elderly, 11.1% to 21.1% [90.1% relative increase, $p=0.002$]; and elderly, 6.4% to 18.0% [2.8-fold increase, $p=0.001$]). Among the 4 histology types (Fig. 3), only serous (13.8% to 29.7%, 2.2-fold increase, $p<0.001$) and clear cell (1.4% to 4.8%, 3.4-fold increase, $p=0.014$) types showed interval increases in the utilization of NACT, with the clear cell type exhibiting the largest interval increase. This increase was not observed for the mucinous and endometrioid types ($p>0.05$ for both).

Survival analysis examining cases from 2002 to 2011 ($n=24,041$) showed that the median follow-up for censored cases was 5.0 (interquartile range, 3.6–5.7) years, with 6,992 (29.5%) deaths occurring because of ovarian cancer. Among the entire cohort, the 5-year CSS rate

| Table 1. Patient demographics |
|-------------------------------|
| Characteristic | NACT/IDS | PDS | p-value |
| No. of patients | 5,153 (10.6) | 43,273 (98.4) | 0.001 |
| Age (yr) | 61 (IQR 53–68) | 56 (IQR 48–65) | <0.001 |
| <65 | 3,236 (62.8) | 31,971 (73.9) | 0.001 |
| 65–74 | 1,403 (27.2) | 7,878 (18.2) | 0.001 |
| >75 | 514 (10.0) | 3,424 (7.9) | 0.001 |
| Registry area | | | 0.001 |
| North | 466 (9.0) | 3,809 (8.8) | 0.001 |
| Central | 718 (13.9) | 5,739 (13.3) | 0.001 |
| East | 2,181 (42.3) | 12,455 (40.3) | 0.001 |
| West | 1,788 (34.7) | 16,270 (37.6) | 0.001 |
| Year at diagnosis | | | 0.001 |
| 2002–2005 | 714 (13.9) | 7,977 (18.4) | 0.001 |
| 2006–2010 | 1,571 (30.5) | 14,247 (32.9) | 0.001 |
| 2011–2015 | 2,868 (55.7) | 21,049 (48.6) | 0.001 |
| Histology | | | 0.001 |
| Serous | 4,194 (81.4) | 15,539 (35.9) | 0.001 |
| Mucinous | 164 (3.2) | 6,181 (14.3) | 0.001 |
| Endometrial | 363 (7.0) | 8,947 (20.7) | 0.001 |
| Clear cell | 432 (8.4) | 12,606 (29.1) | 0.001 |
| Staging surgery | | | 0.001 |
| Performed | 1,885 (36.6) | 19,852 (45.9) | 0.001 |
| Not performed/unknown | 3,268 (63.4) | 23,421 (54.1) | 0.001 |

Number (percent per group) or median (IQR) is shown.

IDS, interval debulking surgery; IQR, interquartile range; NACT, neoadjuvant chemotherapy; PDS, primary debulking surgery.
significantly increased from 59.5% to 72.3% during the study period (21.5% relative increase, \( p=0.015 \); Fig. 4).

The present study demonstrated a significant increase in the utilization of NACT in Japan, with one in 7 women with epithelial ovarian cancer receiving NACT in 2015. This increased use of
NACT was particularly prominent in elderly women as well as those with clear cell histology. Our study also indicated cohort-level increases in the utilization of NACT as well as 5-year survival rates. A recent study in a US population also reported a shift toward the use of NACT that was associated with a decrease in postoperative mortality and improved cohort-level survival [11].

Fig. 3. Histology-specific trends of neoadjuvant chemotherapy. Y-axis is truncated to 0%–30%. Proportion in the utilization of neoadjuvant chemotherapy for histological subtypes per calendar year is shown among all primary epicedial ovarian malignancy. Lines represent modeled estimates and dots represent actual observed values. *p<0.05.

Fig. 4. Temporal trends of the 5-years cause-specific survival rates (cohort level). Y-axis is truncated to 50%–100%. The 5-years cause-specific survival rate with ovarian cancer per calendar year is shown. Lines represent modeled estimates. Dots represent actual observed values and bars represent 95% confidence interval.
Patient selection for NACT/IDS should be personalized based on tumor histology because chemo-resistant tumors such as clear cell carcinoma may be disadvantageous to this treatment strategy. Japanese women have a higher frequency of clear cell carcinoma occurrence compared with that seen in the US or other Western countries [2]. Therefore, NACT/IDS may not always be a substitute for PDS for the initial treatment of epithelial ovarian cancer in Japanese women. Further studies are required to assess the association between NACT/IDS and this specific histology.

Our study has some limitations. This was a retrospective study; therefore, there may be confounding factors that could have affected the results. For instance, data for cancer stage prior to NACT, indications for NACT, and tumor differentiation to distinguish high-grade and low-grade serous tumors were not available in the JSOG database. Moreover, the database only focuses on leading hospitals in Japan, such as university hospitals and cancer centers, thereby increasing the possibility of selection bias.

In conclusion, there was a significant increase in the use of NACT for epithelial ovarian cancer in Japan. The shift toward NACT may be associated with improved survival among the entire cohort. While this trend may be encouraging for the treatment of chemo-sensitive tumors with high-grade serous ovarian cancer, its oncological safety remains undetermined in chemo-resistant histology types. Therefore, consideration of NACT/IDS in women with ovarian cancer requires careful counseling and individualized treatment discussions with patients due to the unknown safety of this treatment among this population.

SUPPLEMENTARY MATERIAL

Supplementary Fig. 1
Selection criteria.

Click here to view

REFERENCES

1. Cancer Information Service, National Cancer Center Japan. Cancer registry and statistics [Internet]. Tokyo: National Cancer Center Japan; 2018 [cited 2019 Jul 16]. Available from: https://ganjoho.jp/reg_stat/statistics/.

2. Machida H, Matsuo K, Yamagami W, Ebina Y, Kobayashi Y, Tabata T, et al. Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: a JSGO-JSOG joint study. Gynecol Oncol 2019;153:589-96.
PUBMED | CROSSREF

3. National Comprehensive Cancer Network (US). NCCN Clinical Practice Guidelines in Oncology. Epithelial ovarian cancer/fallopian tube cancer/primary peritoneal cancer and less common histopathologies [Internet]. Fort Washington, PA: National Comprehensive Cancer Network; 2019 [cited 2019 Jun 5]. Available from: https://www.nccn.org/professionals/physician_gls/default.aspx.
PUBMED | CROSSREF

4. Onda T, Satoh T, Saio T, Kasamatsu T, Nakanishi T, Nakamura K, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer 2016;64:22-31.
PUBMED | CROSSREF

5. Kehoe S, Hook J, Nankiwell M, Jayson GC, Kitchener H, Lopes T, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet 2015;386:249-57.
PUBMED | CROSSREF
6. Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-53.

7. Yamagami W, Nagase S, Takahashi F, Ino K, Hachisuga T, Aoki D, et al. Clinical statistics of gynecologic cancers in Japan. J Gynecol Oncol 2017;28:e32.

8. Ministry of Health, Labour and Welfare (JP). Tokyo: Ministry of Health, Labour and Welfare; Year [cited 2019 Jul 16]. Available from: https://www.mhlw.go.jp/english/.

9. Definition of older people: time to reconsider the definition? Nihon Ronen Igakkai Zasshi 2019;56:1-5.

10. Kim HJ, Fay MP, Feuer EJ, Midthune DN. Permutation tests for Joinpoint regression with applications to cancer rates. Stat Med 2000;19:335-51.

11. Horner W, Peng K, Pleasant V, Brackmann M, Ebbott J, Gutfreund R, et al. Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy. Gynecol Oncol 2019;154:283-9.